StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Exelixis's total debt was $189.12M at Dec 31, 2016. For fiscal 2016 it was $189.12M, down 54.7% from the year before. The highest annual figure on record is $417.94M in fiscal 2015.

Annual total debt

PeriodPeriod endValueChange
FY2016Dec 31, 2016$189.12M-54.7%
FY2015Dec 31, 2015$417.94M+17.1%
FY2014Dec 31, 2014$356.97M+2.8%
FY2013Dec 31, 2013$347.24M+3.4%
FY2012Dec 31, 2012$335.74M+85.0%
FY2011Dec 31, 2011$181.52M-12.9%
FY2010Dec 31, 2010$208.46M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2016Dec 31, 2016$189.12M–

More Exelixis figures

See a number that looks wrong?